Researchers from Genentech Inc. have developed a novel single-domain antibody (VHH) targeting the IL-23 signaling pathway, which can be administered orally to effectively treat inflammatory bowel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results